Brief by Shorts91 Newsdesk / 04:18pm on 29 Jan 2026,Thursday Business
British pharmaceutical giant AstraZeneca announced Thursday it will invest $15 billion in China through 2030 to expand pharmaceutical manufacturing and R&D capabilities. The investment will leverage China's scientific excellence, advanced manufacturing, and China-UK healthcare ecosystem collaborations to deliver cutting-edge treatments globally. UK Prime Minister Keir Starmer, currently on an official visit to China, stated the expansion will support thousands of UK jobs. The company plans to develop existing facilities in Wuxi, Taizhou, Qingdao, and Beijing, while establishing new sites. CEO Pascal Soriot emphasized advancing breakthrough treatments like cell therapy and radioconjugates. The investment is expected to grow AstraZeneca's China workforce beyond 20,000 employees. (PC: Marcus Brandt/dpa & X)
